What is CYP2C19 genetic testing?
Clopidogrel genotype testing is used to detect variation in the CYP2C19 gene that codes for one of the enzymes responsible for metabolizing clopidogrel into its active form.
What does CYP2C19 rapid metabolizer mean?
In people who are rapid metabolizers, the CYP2C19 enzyme has high activity. People who are rapid metabolizers break down some medicines quickly and may need different doses or a different medicine. About 29% of our patients are rapid metabolizers.
What is the CYP2C19 gene?
The CYP2C19 gene provides instructions for making an enzyme that is found primarily in liver cells in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport.
Who is a CYP2C19 poor metabolizer?
Individuals who carry 2 non-functional copies of the CYP2C19 gene are classified as CYP2C19 poor metabolizers. They have no enzyme activity and cannot activate clopidogrel via the CYP2C19 pathway, which means the drug will have no effect.
What medications are affected by CYP2C19?
CYP2C19 catalyzes the metabolism of several drugs, including proton pump inhibitors (PPIs) (e.g., omeprazole, lansoprazole, pantoprazole), antidepressants (e.g., citalopram and amitriptyline), antiplatelet drugs (e.g., clopidogrel), antifungals (e.g., voriconazole), and anticancer compounds (e.g., cyclophosphamide).
Does everyone have CYP2C19?
This results in very little to no CYP2C19 activity. About 2 out of 100 people have this gene status. Certain drugs should be avoided and patients may need to have their doses of some medications adjusted. Other clinical factors (diet, other drugs, diseases) may influence your response to medications.
The CYP2C19 gene provides instructions for making an enzyme that is found primarily in liver cells in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport.
What is the prevalence of the CYP2C19*17 variant?
In order for the studies on CYP2C19*17 to be conclusive, the differences in other genes that affect drug response have to be excluded. The prevalence of the CYP2C19*17 variant is less than 5% in Asian populations and is approximately four times higher in European and African populations.
Are gene variants in CYP2C19 associated with altered in vivo bupropion pharmacokinetics?
“Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes”. Drug Metabolism and Disposition. 42 (11): 1971–7. doi: 10.1124/dmd.114.060285.
Do polymorphisms of the CYP2C19 gene differ among Han populations?
Conclusion: This is the first study that systematically screened the polymorphisms of the whole CYP2C19 gene in a large Chinese Han population. The results suggest that a few low frequent variants show significant differences among the four populations, while the prevalent polymorphisms show no differences.